



**Renalytix plc  
("Renalytix" or the "Company")**

**Director / PDMR Share Purchase**

**LONDON and NEW YORK, 13 February 2026** Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, whose product *kidneyintelX.dkd*, is the only FDA-approved and Medicare-reimbursed prognostic test to support early-stage risk assessment in chronic diabetic kidney disease, announces that on 11 February 2026 Joel Jung, interim Chief Financial Officer, bought a further 500 American Depositary Shares (ADS) at a price of US 2.85 per ADS. ADS consist of 50 Ordinary Shares of £0.0025 each.

Following this transaction, Joel Jung is interested in 333,855 Ordinary Shares representing 0.07% of the issued share capital of the Company.

**For further information, please contact:**

**Renalytix plc**

James McCullough, CEO

[www.renalytix.com](http://www.renalytix.com)

Via Walbrook PR

**SP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)**

Tel: +44 (0)20 3470 0470

Jeff Keating / David Hignell (Corporate Finance)  
Vadim Alexandre (Corporate Broking)

**Oberon Capital (Joint Broker)**

Tel: +44 (0)20 3179 5300

Mike Seabrook / Nick Lovering

**Walbrook PR Limited**

Paul McManus / Alice Woodings

Tel: +44 (0)20 7933 8780 or [renalytix@walbrookpr.com](mailto:renalytix@walbrookpr.com)

Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

**About Renalytix ([www.renalytix.com](http://www.renalytix.com))**

Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled *in vitro* diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes. Renalytix has received FDA approval and Medicare reimbursement for *kidneyintelX.dkd* which is now offered commercially in the United States.

Unrecognized and uncontrolled diabetic kidney disease remains one of the largest barriers to controlling cost and suffering in the United States and the United Kingdom's medical system, affecting approximately 15 million and 8 million people, respectively. After five years of development and clinical validation, *kidneyintelX.dkd* is the only FDA-approved and Medicare-reimbursed prognostic tool capable of understanding a patient's risk with diabetic kidney disease early where treatment has maximal effect. *kidneyintelX.dkd* is now being deployed across large physician group practices and health systems in select regions of the United States.

The over 15,000 patients that have been tested by *kidneyintelX.dkd* have produced a substantial body of real-world performance data. In patient populations where *kidneyintelX.dkd* has been deployed, a demonstrated and significant increase in diagnosis, prognosis, and treatment rates have been recorded. *kidneyintelX.dkd* now has full reimbursement established by Medicare, the largest insurance payer in the United States, at \$950 per reportable result. *kidneyintelX.dkd* is also recommended for use in the international chronic kidney disease clinical guidelines (KDIGO).

*KidneyIntelX* is based on technology developed by Mount Sinai faculty and licensed to Renalytix AI, Inc. Mount Sinai faculty members are co-founders and equity owners in the Company. In addition, the Icahn School of Medicine at Mount Sinai has equity ownership in Renalytix. For information about the *kidneyintelX.dkd* test, visit [kidneyintelx.com](http://kidneyintelx.com).

**Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them**

<b>1</b>	<b>Details of the person discharging managerial responsibilities / person closely associated</b>					
a)	Name	Joel Jung				
<b>2</b>	<b>Reason for the notification</b>					
a)	Position/status	interim Chief Financial Officer				
b)	Initial notification /Amendment	Initial Notification				
<b>3</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>					
a)	Name	Renalytix plc				
b)	LEI	213800NTOH3FK3WER551				
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>					
a)	Description of the financial instrument, type of instrument  Identification code	American Depositary Shares (ADS) which consist of 50 Ordinary Shares at £0.0025 each  GB00BYWL4Y04				
b)	Nature of the transaction	Purchase of Ordinary Shares				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>2.85</td> <td>500</td> </tr> </tbody> </table>	Price(s)	Volume(s)	2.85	500
Price(s)	Volume(s)					
2.85	500					
d)	Aggregated information - Aggregated volume - Price	500 1,425				
e)	Date of the transaction	11 February 2026				
f)	Place of the transaction	OTC New York				

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHEAXAAFSNKEFA